BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 14528280)

  • 1. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
    Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
    Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD105 is important for angiogenesis: evidence and potential applications.
    Duff SE; Li C; Garland JM; Kumar S
    FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoglin (CD105): a target for anti-angiogenetic cancer therapy.
    Fonsatti E; Altomonte M; Arslan P; Maio M
    Curr Drug Targets; 2003 May; 4(4):291-6. PubMed ID: 12699349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
    Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
    J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
    Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
    Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
    Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
    Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.
    Dallas NA; Samuel S; Xia L; Fan F; Gray MJ; Lim SJ; Ellis LM
    Clin Cancer Res; 2008 Apr; 14(7):1931-7. PubMed ID: 18381930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
    Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
    Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer.
    Yoshitomi H; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Miyazaki M
    Pancreas; 2008 Oct; 37(3):275-81. PubMed ID: 18815549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
    Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
    Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
    Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
    Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors.
    Adam M; Schmidt D; Wardelmann E; Wernert N; Albers P
    Eur Urol; 2003 Sep; 44(3):329-36. PubMed ID: 12932931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
    Li C; Guo B; Bernabeu C; Kumar S
    Microsc Res Tech; 2001 Feb; 52(4):437-49. PubMed ID: 11170303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
    Netto GC; Bleil CB; Hilbig A; Coutinho LM
    Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
    Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
    Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.
    Nassiri F; Cusimano MD; Scheithauer BW; Rotondo F; Fazio A; Yousef GM; Syro LV; Kovacs K; Lloyd RV
    Anticancer Res; 2011 Jun; 31(6):2283-90. PubMed ID: 21737653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.
    Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
    Pathol Int; 2006 Dec; 56(12):717-23. PubMed ID: 17096728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.